Drug: CellCept (mycophenolate mofetil)

Manufacturer: Genentech

Route of Administration: Oral

Site of Care: Outpatient

Approved Indication: prophylaxis of organ rejection in adult and pediatric recipients 3 months of age and older of allogenic kidney, heart, or liver transplants, in combination with other immunosuppressants

Disease: solid organ transplant

Therapeutic Area: Solid Organ Transplant

Enrollment Form Link: www.mycophenolaterems.com

Phone Number: N/A

Fax Number: N/A

Product Website: cellcept.com